Cite
Lothgren M, Ribnicsek E, Schmidt L, et al. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013;20(4):227-231doi: 10.1136/ejhpharm-2012-000235.
Lothgren, M., Ribnicsek, E., Schmidt, L., Habacher, W., Lundkvist, J., Pfeil, A. M., Biteeva, I., Vrouchou, P., & Bracco, A. (2013). Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. European journal of hospital pharmacy : science and practice, 20(4), 227-231. https://doi.org/10.1136/ejhpharm-2012-000235
Lothgren, Mickael, et al. "Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland." European journal of hospital pharmacy : science and practice vol. 20,4 (2013): 227-231. doi: https://doi.org/10.1136/ejhpharm-2012-000235
Lothgren M, Ribnicsek E, Schmidt L, Habacher W, Lundkvist J, Pfeil AM, Biteeva I, Vrouchou P, Bracco A. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013 Aug;20(4):227-231. doi: 10.1136/ejhpharm-2012-000235. Epub 2013 Feb 21. PMID: 23888248; PMCID: PMC3717600.
Copy
Download .nbib